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Abstract
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CD2 and CD58 are two important co-stimulatory molecules involved in generating the signal II
required for normal immune signaling. However, this interaction can be targeted to be of benefit in
cases of abnormal immune signaling seen in autoimmune diseases. Our objective in this study was
to design a peptidomimetic (compound 7) based on a β-strand structure of the adhesion domain of
CD2 protein to inhibit CD2-CD58 protein-protein interaction and its effect on immunomodulation
in the collagen-induced arthritis (CIA) model. The ability of compound 7 to bind to CD58 protein
was assessed using flow cytometry. The effect of compound 7 on modulating the immune
response was evaluated in an autoimmune disease using CIA in mice. The stability of compound 7
was evaluated in mouse serum using mass spectrometry. Antibody (Ab) binding inhibition studies
suggested that compound 7 binds to CD58 protein. Compound 7 was successful in modulating
immune responses when administered in the CIA mouse model along with reducing anti-collagen
Ab levels and decreasing the level of interferon gamma (IFN-γ) relative to control treatments.
Compound 7 was found to be non-immunogenic and stable in mouse serum up to 48 h. Results
suggest that compound 7 can serve as a lead compound for immunomodulation, and could be a
therapeutic agent for the autoimmune disease rheumatoid arthritis (RA).
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INTRODUCTION
Three major families of cell surface receptor molecules that provide signaling for costimulation include the B7-CD28 superfamily, lymphocyte associated antigen-1 (LFA-1)

**
Correspondence to: Seetharama Jois, Ph.D. Associate Professor, Basic Pharmaceutical Sciences, School of Pharmacy University of
Louisiana at Monroe, 1800 Bienville Drive, Monroe LA 71201, Tel: 318-342-1993, Fax: 318-342-1737, jois@ulm.edu.

Gokhale et al.

Page 2

Author Manuscript

and intercellular adhesion molecule-1 (ICAM-1), and the CD2 superfamily1. CD58 on the
surface of the antigen-presenting cells (APC) binds to CD2 on the T-cell surface following
T-cell receptor (TCR) engagement. Specifically, the interaction of CD2 with CD58 enhances
the TCR-peptide-major histocompatibility complex (pMHC) affinity by 100-fold. Upon
interaction of CD2 with CD58, the cytoplasmic domain of CD2 initiates a cascade of signals
to enhance interleukin-2 (IL-2) production that promotes T-cell survival2–6. In contrast,
TCR signaling in the absence of co-stimulation can have a negative regulatory effect on Tcell activation. Therapeutic strategies that are developed to block the co-stimulatory
pathways include the use of monoclonal antibodies, small molecule or peptide inhibitory
compounds, and fusion proteins. Blocking or modulating CD2-CD58 signaling has been
shown to have therapeutic utility for dampening immune responses7,8. Rheumatoid arthritis
(RA) is an autoimmune disorder that is inflammatory in nature and affects multiple joints
(polyarthritis). During the progression of the disease, cartilage destruction caused by over
recruitment of T-lymphocytes occurs at the joints. It has been postulated that, in the
pathology of RA, there is overexpression of CD58 within affected tissues that provides an
abundance of CD2 signaling to local T cells9. Hence, targeting the CD2-CD58 adhesion and
co-stimulation signal for therapeutic intervention is beneficial in the treatment of RA10.
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Our interest is to design peptides and peptidomimetics that inhibit or modulate CD2-CD58
interaction and suppress immune responses in the collagen-induced arthritis (CIA) mouse
model. In our earlier studies, we have reported that peptides designed from CD2 protein
inhibit cell adhesion and modulate immune response (Figure 1)11–15. In the present work,
we extend our studies to a peptidomimetic with a dibenzofuran moiety (DBF) (compound
7). Peptides with a dibenzofuran moiety that induces β-hairpin structure have been reported
by other research groups16,17. Such peptidomimetics are useful because they often show
increased stability against enzymatic degradation18–20. Compound 7 has been designed
using the CD58 binding domain of CD2 protein based on our previous structure-activity
relationship studies and has a β-strand structure that is stabilized by DBF moiety (Figure 2).
In addition to inducing a β-strand structure, DBF also mimics a beta turn. The sequence of
the CD2 adhesion domain was reversed in compound 7 to exhibit potential cell adhesion
activity15. Our results show that compound 7 suppressed the progress of RA in a murine
CIA mode. This suppression was accompanied by a reduction in collagen antibody levels
and inflammatory cytokine production.

MATERIALS AND METHODS
Materials

Author Manuscript

All cells and media were purchased from American Type Culture Collection (ATCC)
(Rockville, MD, USA). FITC labeled antibody CD58 (FITC CD58Ab) was purchased from
BD Biosciences (San Jose, CA). Flow cytometry studies were performed on BD FACS
Calibur (BD Biosciences, San Jose, CA). Type II collagen, Complete Freund’s Adjuvant
(CFA) and incomplete Freund’s adjuvant were purchased from Chondrex, Inc. (Redmond,
WA). CellTiter-Glo assay kit was purchased from Promega, Inc. (Springfield, MO).
Conconavalin A was purchased from GE Healthcare (Pittsburg, PA). The BD bio-array kit
for cytokine levels determination was purchased from BD Biosciences. Immulon II plates
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were purchased from Dynex technologies (VA). Tetramethyl benzidine was obtained from
Kirkegard and Perry labs (Gaithersburg, MD). 4-(Fmoc-2-aminoethyl)-6dibenzofuranpropionic acid was from Chem-Implex International (Wood Dale, IL) and all
the amino acids and chemical reagents for peptide synthesis were from Applied Biosystems
(Lifetechnologies, Grand Island, NY).
Synthesis of compound 7
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Compound 7 was synthesized using standard solid-phase Fmoc chemistry21 using 2chlorotrityl chloride resin (3 g, 0.89 mmol/g). After allowing the resin to swell in
dichoromethane, it was then loaded with a solution of Fmoc-Ile-OH and N,Ndiisopropylethylamine (DIEA) in 30 mL of dichloromethane. The mixture was agitated for 2
h, then filtered and washed with N-methyl-2-pyrrolidone (NMP) (30 mL, 6 × 30 sec),
dichloromethane/methanol/N,N-diisopropylethylamine (DCM/MeOH/DIEA) (80:15:5, 2 ×
15 min), NMP (5 × 30 sec), and dichloromethane (5 × 30 sec). The resin was dried under
vacuum overnight and then deprotected with 30 mL of 20% piperidine/NMP (2 × 5 min).
The remainder of the peptide sequence was synthesized using an automatic peptide
synthesizer (Tribute Synthesizer). All amino acids (including DBF) were coupled using 5
equivalents of Fmoc-protected amino acid and 5 equivalents of 2-(6-chloro-1Hbenzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) dissolved in
2 mL of a 0.4 M solution of 4-methylmorpholine in NMP. The amino acid solution was
bubbled on the instrument for 2 min before it was added to the resin after which the resin
was shaken for 30 min. The resin was then washed with DMF (5 × 30 sec) and then
deprotected with 20% piperidine/NMP (2 × 5 min). This sequence was repeated for the
remaining amino acids in the sequence using the synthesizer. After the last amino acid was
added to the peptide, the final Fmoc protecting group was removed. The peptide was
cleaved from the resin by adding 2,2,2-trifluoroethanol:dichloromethane (2 mL, 1:1) to the
resin and agitating it for 3 h. The cleavage step was repeated 3 times. Cyclization of the
peptide was performed after the cleavage of the peptide from the resin. The cleavage
solutions were then combined, and the solution was evaporated at room temperature under a
gentle stream of nitrogen. The remaining solid was dissolved in 100 mL of tetrahydrofuran
(THF)/DMF (4:1) to which was added 3-hydroxy-3H-1,2,3-triazolo[4,5-b]pyridinatoO)tri-1-pyrrolidinyl-phosphorus hexafluorophosphate (PyAOP) (4 eq., 104 mg) and DIEA
(7 eq, 70 μL). The solution was agitated for 2 h after which the solvent was evaporated
under vacuum to yield a solid. The crude cyclic peptide was then treated with a deprotection
cocktail (4 mL, trifluoroacetic acid (TFA):water:triisopropylsilane (TIPS), 95:2.5:2.5) for 3
h. The peptide solution was poured into a 50 mL centrifuge tube, and the peptide was
precipitated with 30 mL of cold diethyl ether. The tube containing the peptide was
centrifuged and the supernatant was removed. The crude peptide was dissolved in 0.1%
TFA/water, and lyophilized to obtain a white powder as the crude peptide. For in vivo
studies, compound 7 was custom synthesized by Aroz Technologies, LLC (Cincinnati, OH).
Compound 7 was purified by HPLC, and the purity of the final product was determined
using analytical HPLC, electrospray mass spectrometry (ESI-MS). High-resolution mass
spectrometry data were obtained. The calculated exact mass of compound 7 was 1014.4334
and the m/z obtained from experimental high-resolution mass spectrometry data was

Biopolymers. Author manuscript; available in PMC 2016 November 01.

Gokhale et al.

Page 4

Author Manuscript

1014.4339 (Supporting Information). A detailed NMR structure of compound 7 has been
reported15.
Competitive binding studies
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The ability of compound 7 to bind to CD58 on Caco-2 cells was evaluated using FITCCD58Ab in a competitive binding experiment and using flow cytometry and fluorescence
plate reader assay in two different sets of experiments. Details of the procedures were
published elsewhere 22. Briefly, Caco-2 cells were distributed in 7 different vials and 50 μL
of FITC-labeled anti-CD58 with or without 100 μL of compound 7 was added at different
concentrations. Cells with fluorescently labeled anti-CD58 were incubated at 4 °C for 30
min and then subjected to 720 × g at room temperature for 10 min, resuspended in 4–5 mL
of PBS, and transferred into flow cytometry tubes on ice. The samples were analyzed using
a BD FACS flow cytometer. For the fluorescence assay using a plate reader, cells were
incubated with FITC-CD58Ab (pre-diluted, 20 μL) and/or compound 7 for 1 h after they
reached confluency. The plate was washed 3 times after incubation, and fluorescence was
read using a microplate reader at excitation λ 485 nm and emission λ 528 nm. Data were
obtained as a set of triplicates. Fluorescence from the blank was subtracted for the final
representation.
In vivo studies

Author Manuscript
Author Manuscript

Female DBA/1 mice 6–7 weeks old were obtained from Harlan Laboratories (Indianapolis,
IN) and maintained in the ULM School of Pharmacy vivarium. Animal studies were
conducted in strict accordance with good animal practice as defined by NIH guidelines, and
all animal work was approved by the IACUC, University of Louisiana at Monroe (ULM).
Animals were divided into six groups with eight mice in each group. The groups were G1control, G2-arthritic mice, G3-arthritic mice treated with control peptide, G4-arthritis mice
treated with compound 7 at a concentration of 1 mg/kg, G5-arthritis mice treated with
compound 7 at a concentration of 0.5 mg/kg, and G6-mice treated with compound 7 at a
concentration of 0.25 mg/kg. The induction of arthritis in the DBA-1 strain of mice was
performed through the intradermal route of administration using type II collagen formulation
(CII) emulsified in CFA following published procedures23–25. Emulsion containing 3
mg/mL of CII (100 μL) was injected intradermally at the base of the tail for the first
immunization. A booster injection of CII emulsified (with incomplete Freund’s adjuvant
(IFA)) was given on day 21 of the study23,24. The peptides were dissolved in PBS and
treatment was started on 22nd day through intravenous tail-vein injection. A total of 5
injections of compound 7 and control peptide (1 mg/kg) in PBS were given on alternate
days. The monitoring of mice was started on day 21 to determine the onset and severity of
the disease. Wrist and ankle joints were inspected on alternate days beginning on the 21st
day post-immunization. The visual appearance of the limbs was graded on a scale of 0–
424,26. A Mann Whitney test using graph pad prism was performed to determine the
statistical difference among the different groups for days 30 to 46. A one-way ANOVA was
performed to determine the statistical significance among various treatment groups.
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Histopathology for disease progression and suppression was performed on samples obtained
from hind limbs in 4 mice from each group on day 57 after mice were sacrificed. Hind limbs
were fixed in 10% formalin and decalcified in EDTA for 60 days. Decalcification was
verified by adding oxalic acid and observing the precipitate. Sections were stained with
haematoxylin and eosin (H & E).
T-cell proliferation assay
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This assay required the immunization of DBA-1 female mice with 100 μg of native type II
collagen emulsified with CFA 12 days prior to the actual day of assay. APC were generated
from naïve mice without type II collagen injection. Spleen cells were isolated from the
immunized and control mice. T cells were filtered using a pre-washed nylon column and
published procedures22. Spleens of normal mice were collected in a similar manner. 0.1 mL
(4 × 106) of enriched T cells, 0.1 mL (1 × 107) of APC, and 10–20 μL of 1 mg/mL
arthrogen-CIA T-cell grade type II collagen were seeded in 96-well flat bottom plates and
incubated at 37 °C for 3 days in a CO2 incubator. After harvesting the cells, compound 7
was added at different concentrations. Inhibition studies were also carried out with the
addition of anti-CD4 and anti-CD8 antibodies to culture wells. Similar experiments were
performed using control peptide26,27. Concanavalin (Con A) was used as a positive control
whereas medium containing only cells was used as a negative control.
Cytokine analysis
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The levels of different cytokines from the blood of mice were determined using the BD
Cytometric Bead Array Th1/Th2 kit. The test samples were diluted by 1:100 dilution factors
using the assay diluents and were mixed properly. 50 μL of the mouse Th1/Th2 PE detection
reagent was added to all assay tubes, and the tubes were further incubated for 2 h at room
temperature protected from light. After incubation, 1 mL of wash buffer was added in each
tube and centrifuged at 200 × g for 5 min. The supernatant was discarded and 300 μL of
wash buffer was added to each tube to resuspend the bead pellet. Finally, mouse Th1/Th2
cytokine data were analyzed using flow cytometry.
Measurement of anti-collagen Ab levels
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Serum was collected from blood samples by centrifugation at 2000 rpm. Levels of anticollagen antibodies were determined using this serum in various groups of mice. Immulon II
plates were coated with bovine type II collagen (1 μg/mL, 0.1 mL/well) in carbonate/
bicarbonate buffer and kept at 4 °C overnight. The next day they were washed with PBS
containing 0.05% Tween-20 and blocked with 1% BSA for 30 minutes. Serum samples were
diluted 50-fold in 1% BSA followed by threefold serial dilutions. These samples were added
in triplicate into each well (50 μL) and incubated for 2 h at room temperature. Bound anticollagen Abs were determined using HRP-labeled goat anti-mouse IgG. Tetramethyl
benzidine (100 μL/well) was added to each well and allowed to develop color before
stopping the reaction with 1 M sulfuric acid. Absorbance was read at 450 nm with
background subtraction at 630 nm28. Readings were in triplicate and the experiment was
repeated twice.
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200 μL of stock solutions of compound 7 was treated with 1 mL of purchased serum
(Sigma-Aldrich, St Louis, MO). At different time points ranging from 0 min to 48 h, 100 μL
of the above sample was withdrawn and treated with 500 μL of chilled acetonitrile for
compound 7 extraction. This sample was vortexed followed by centrifugation at 13,000 × g
for 15 min. The supernatant was passed through a SEP-PAK C18 column and lyophilized 29.
These samples were analyzed by TOF-MS. The matrix was prepared as a 10 mg/mL solution
of α-cyano-4-hydroxy-cinnamic acid (Sigma) in 2:1 water:acetonitrile containing 0.1% TFA
by volume. A 5 μL aliquot of the sample solution was combined with 5 μL of the matrix
solution. 1 μL of this mixture was spotted onto a MALDI target plate and allowed to dry.
MALDI-TOF MS measurements were performed on Ultraflextreme (Bruker Daltonics,
Billerica, MA). Leuprolide (Sigma-Aldrich) was used as an internal standard (molecular
weight 1209)30. The relative intensity of the peak vs. time was plotted.

RESULTS
Synthesis of compound 7
Compound 7 was synthesized by solid-phase peptide synthesis.21 The compound was
cleaved from the resin using a TFA cocktail and purified by HPLC with a C-18 column. The
product was analyzed for purity using analytical HPLC and mass spectrometry. The
structure of compound 7 was characterized by circular dichroism (CD) and NMR as
previously reported15.
Competitive binding of compound 7 to CD58 expressed by Caco-2 cells in the presence of
FITC-labeled anti-CD58
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Compound 7 was designed from the surface epitope of the CD2 protein involved in the
binding of CD58. It was presumed that compound 7 will bind to CD58 and inhibit the
protein-protein interactions of CD2 and CD58, resulting in cell adhesion inhibition between
T cells and Caco-2 cells. The binding of compound 7 to CD58 was evaluated using Caco-2
cells that express CD58 in the presence of FITC-CD58Ab using a fluorescence assay and
flow-cytometry analysis. Expression of CD58 protein on Caco-2 cells was verified by
binding of FITC-CD58Ab. Compound 7 was incubated at increasing concentrations (0.05 to
10 μM) in the presence of FITC-CD58Ab, and relative fluorescence was measured using a
plate reader in the fluorescence assay. The fluorescence intensity of FITC-CD58Ab was
measured; it was found that in the presence of compound 7, CD58Ab binding was decreased
substantially even at low concentration of 0.05 μM. This indicated the competitive binding
of compound 7 to CD58 protein on Caco-2 cells (Figure 3). In the second set of experiments
using flow-cytometry, similar results were obtained. Assessment of Caco2 cells labeled with
FITC-CD58Ab and incubated with increasing concentrations of compound 7 (10 to 200
μM), showed a shift of labeled cells toward the left in the histogram compared to the cell
population that was labeled with FITC-CD58Ab, suggesting the competitive binding of
compound 7 to CD58. At 200 μM of compound 7, nearly 85% inhibition of antibody binding
was observed (Figure 4).
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The in vivo effect of compound 7 to suppress the progression of arthritis was evaluated in an
autoimmune disease model, collagen-induced arthritis (CIA) in DBA/1 mice. DBA/1 mice
were induced with arthritis using type II collagen. After induction of arthritis, compound 7
was administered through i.v. injection starting on day 22; treatment was then continued for
5 doses administered on alternate days. To assess the disease progression, scoring system by
visual appearance of limbs and digits was used23,31. Compound 7 at 1 mg/kg, 0.5 mg/kg,
and 0.25 mg/kg showed significant reduction in arthritis score from days 40 to 46 as
compared to control peptide and untreated mice group (Figure 5). The Mann Whitney U
Test was applied using a 95% confidence interval to determine the statistical significance
and variability within the groups. There was a significant difference (with P <0.05) between
the control peptide vs. compound 7 treated groups with 0.25, 0.5, and 1 mg/kg treatment.
However, when we compared the treatment groups at different doses of compound 7, there
were no significant differences observed between mice treated with 0.5 mg/kg and 1 mg/kg
of compound 7. The mice did not show any clinical signs of illness such as anorexia,
hunched posture, ruffled fur, and/or lethargy during dosing or prior to the onset of observed
clinical arthritis.
Histopathology analysis of tissue samples
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Histopathology analysis of tissue samples of limbs was carried out using H&E stained slides
from different groups of mice. In the normal animals, it was seen that surfaces of cartilage
were smooth and intact. Articular cartilaginous surfaces of both bones were intact, with a
smooth and clear joint space as seen in Figure 6A. This result correlates with the visual
scoring of the hind limbs of the normal group of mice where there was no inflammation seen
at the joints. The H & E stain (original 100× magnification) of the arthritis group of
phalangeal joints with severe (Grade 4) arthritis indicated the cartilaginous erosion of joint
surface and pannus formation around the cartilage. There was a significant infiltration of
mononuclear cells surrounding the pannus formation as seen in Figure 6B. This observation
was supported by the fact that mice in this group had severe inflammation and reddening
with all digits visually swollen during disease progression. In the case of compound 7 (0.5
mg/kg) treated mice, H & E staining of the hind paw indicated clear joint space with a
normal cartilage interface. Though connective tissue surrounding the joint was heavily
infiltrated with mixed inflammatory cells, there was a reduction in pannus formation as
shown in Figure 6C. These results suggest that compound 7 could suppress the progression
of arthritis in the CIA model.
Compound 7 inhibited the production of anti-collagen Abs
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The degree of severity of arthritis in mice can be evaluated by the quantity of CII-specific
antibody in the serum of a mouse that develops CIA. The autoimmune response to CII can
be evaluated by measuring the quantity of the CII-specific antibody in the sera of the mice.
Serum samples were analyzed at the termination of the study in different groups of mice to
evaluate whether compound 7 can inhibit the production of anti-CII Abs. The results
suggested that compound 7 was able to reduce the amount of CII in mice that developed
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arthritis compared to the control group. This reduction in CII (Figure 7A) suggested that
inhibition of adhesion leads to modulation of the immune response.
Compound 7 reduces level of cytokines in serum of mice
Elevated serum levels of inflammatory cytokines such as TNF-α and IFN-γ and chemokines
like IL-5 are hallmarks of rheumatoid arthritis development and CIA. In RA patients, these
cytokines have been found to be at higher levels than in normal patients and contribute to
further progression of bone and cartilage destruction. We wanted to determine whether
compound 7 could lower the levels of IFN-γ by blocking CD2-CD58 interaction. It was
observed that compound 7 at 1 mg/kg was able to reduce the levels of IFN-γ compared to
those in control peptide treatment and untreated arthritic groups of mice. This indicated that
by inhibiting protein-protein interaction we could lower the levels of cytokines in blood sera
of DBA/1 mice (Figure 7B).

Author Manuscript

Compound 7 immunogenicity
Peptides that are not endogenous to the body can trigger both cellular and humoral immune
responses when administered. We therefore wanted to evaluate whether the peptides
administered into mice are immunogenic or not. This was determined by measuring the
response of isolated splenocytes from primed mice to the peptides in vitro. It was observed
that varying doses of compound 7 did not generate any measurable T-cell memory response
in cultured splenocytes. Compound 7 at either dose (1 or 0.25 μM) did not induce
proliferation of t-cells as compared to controls. Con A was used as a positive control and
indicated proliferation of cells more than 40 times that of compound 7-treated cells (Figure
7C).
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Stability of Compound 7 in mouse serum
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To prevent enzymatically facilitated peptide degradation, several strategies based on the
chemical modification of the peptides are generally applicable32–34. Compound 7 was
incubated in mouse serum, and its stability was evaluated using mass spectrometry. Since in
vivo studies were conducted in a mouse model, use of mouse serum is appropriate. The
stability of compound 7 was assessed by comparing the intensity of the peak in the mass
spectrum30 with that of the freshly prepared leuprolide that was used as internal standard.
The recovery of compound 7 from mouse serum was detectable at all time points, and the
half-life for compound 7 in mouse serum was estimated to be around 2 h (Figure 8). More
accurate quantitative determination of the actual amount of peptide degraded at different
time points will be performed in future studies using HPLC and quantitating the peak area
under the curve.

DISCUSSION
Compound 7 described in the present study was derived from the adhesion region (F and C
strands) of CD2 protein and has been shown previously to block the adhesion interaction
between T cells and epithelial cells by inhibiting CD2-CD58 interaction 6,22. The β-turn/
hairpin in the structure of compound 7 was stabilized by a β-turn mimicking dibenzofuran
moiety16. Competitive binding studies using fluorescence-labeled antibodies suggested that
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compound 7 binds to CD58, presumably to the adhesion domain of CD58, and inhibits the
interaction between CD2-CD58. In the fluorescence assay using Caco-2 cells (Figure 3),
compound 7 exhibited inhibition of antibody binding at as low as 0.05 μM concentration.
Compared to 0.05 μM of compound 7, 0.5 and 10 μM concentrations of compound 7
exhibited higher inhibition of antibody binding. However, there was no clear dose response
of competitive binding of compound 7 to CD58 protein on Caco-2 cells. Since antibody to
CD58 binds to CD58 protein on cells with high specificity at nanomolar concentration, it
may not be possible to completely inhibit FITC-antiCD58 binding to CD58 by compound 7.
We believe that this might be the reason for the results observed (Figure 3) for compound 7.
Our ultimate aim was to design a peptidomimetic which can inhibit CD2-CD58 PPI in the
pathogensis of RA. Compound 7 was able to supress the progression of arthritis at all the
doses, i.e., 0.25, 0.5, and 1 mg/kg, respectively, indicating the ability of peptides to
modulate the immune response in in vivo studies. The suppression of CIA35 was confirmed
by the visual arthritis scoring of the inflammation of the limbs as well as by histopathology
analysis. Compound 7 was able to reduce the levels of IFN-γ compared to the levels in the
arthritic group. Although we have not yet performed dose escalation studies for toxicity
assessment, our observations from in vivo studies did not indicate any toxic effects of the
compound in experimental animals. Compound 7 did not show any immunogenicity36 when
compared to the positive control con A. We can presume that the immunomodulation by
compound 7 occurs by binding to the receptor protein and inhibiting protein-protein
interactions of CD2-CD58/CD48. We have used a cyclization approach to improve the
overall stability of the peptide while preserving its potency by retaining the important
residues of the original adhesion domain sequence of CD2 protein. DBF moiety was added
in compound 7, which imparted β-turn structure in the designed peptidomimetic. Along with
β-turn constraints, cyclization of the peptide backbone helps to confer a structural constraint
that reduces conformational flexibility37. Stability studies indicated that the half-life of
compound 7 in mouse serum was 2 h and that the compound could be detected in serum
even at the 48 h time point (Figure 8). This clearly suggests that compound 7 was stable in
circulation in vivo to exert its pharmacological action. More than 50% of the compound 7
was degraded in 4 h, and the amount of intact compound 7 reached a plateau around 4 h as
seen in Figure 8. One possibility for the observed plateau after about 4 h is that compound 7
is binding to serum proteins38,39. Most of the drug-like molecules/peptides bind to serum
proteins. We have not investigated this in the present work. During extraction, the
compound that is bound to serum protein may be released into organic medium, and we
could detect that during mass spectrometry analysis.

CONCLUSIONS
Author Manuscript

In conclusion, a peptidomimetic compound 7 was designed to modulate the immune
response. Cellular assays and in vivo studies indicated that compound 7 binds to the
adhesion domain of CD58 protein and was able to suppress progression of CIA in the
DBA/1 mouse model. Anti-CII antibody levels were also found to be reduced in mice
treated with compound 7 as were the levels of IFN-γ. Thus, our studies demonstrate that
protein-protein interactions between CD2-CD58 could be modulated by a peptidomimetic in
vivo, and it could be therapeutically useful for treating autoimmune diseases.
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FIGURE 1.

Schematic diagram showing the importance of adhesion molecules CD2-CD58 in immune
response and inhibition of protein-protein interactions of CD2-CD58 by compound 7 and
modulation of immune response.
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FIGURE 2.

Structure of compound 7.
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FIGURE 3.

Author Manuscript

Competitive binding of compound 7 with FITC-labeled antibody to Caco-2 cells expressing
CD58 protein. Antibody binding to Caco-2 cells in the presence of compound 7 at different
concentrations is shown. 1 × 106 cells/100 μL were redistributed into different wells of 96well plates. After 24 h, attached cells were incubated with FITC-CD58Ab (pre-diluted, 20
μL) and/or compound 7 for 1 h. The plate was washed 3 times after incubation and
fluorescence was read using a microplate reader at excitation λ 485 nm and emission λ 528
nm. Fluorescence from the blank was subtracted for representation. Data are from triplicate
experiments.
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FIGURE 4.

Competitive binding of compound 7 with FITC-labeled antibody to Caco-2 cells expressing
CD58 monitored by flow cytometry (BD FACS Calibur). Cells were distributed in 7
different vials and added with 50 μL of FITC-labeled anti-CD58 as positive control, 50 μL
of FITC-CD58Ab along with 100 μL of compound 7 at concentrations of 10, 50, 100 and
200 μM and controls. The shift in number of cells with or without FITC-CD58Ab was
observed. Histograms show Caco-2 cells without peptide or antibody (more than 80% of the
unstained cells are observed), cells with FITC-AbCD58 (there was a shift of cell population
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to the right and nearly 75% of cells were stained), and cells with compound 7 and FITCCD58Ab at compound 7 concentrations of 10, 50, 100, and 200 μM, respectively. Note that
in the presence of compound 7 more Caco-2 cells without antibody labeling (cell population
shifted to left compared to cells + FITC antibody) were observed, suggesting the inhibition
of FITC-CD58Ab to Caco-2 cells. A vertical dotted line was drawn for comparison of shifts
of cells.
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FIGURE 5.

Suppression of collagen-induced arthritis by compound 7. Treatment of mice by compound
7 shows suppression of collagen-induced arthritis (statistically significant) from days 40–46
at concentrations of 0.5 mg/kg and 1 mg/kg when compared to control peptide and vehicle.
Scoring (0–4) was done according to the published procedure as described in the text for all
the four limbs with a maximum score of 16. For plotting, the average score from 8 mice was
used.
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FIGURE 6.
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Histopathological analysis of samples from hind limbs of normal, arthritic, and treated
DBA/1 mice. Sections of paw (interphalangeal joints) and hind limb (tarsal joints) from 12
mice from different groups were examined. Representative sections from the tarsal joints of
three mice are shown above.
(A) Normal tarsocrural joint (tibia and talus). Articular cartilaginous surfaces of both bones
are intact and smooth (arrow heads) and the joint space is clear (*); H&E staining, 200×.
(B) Arthritic proximal intertarsal joint (talus and calcaneus) with grade 4 arthritis. Abundant
pannus with thick articular cartilage in some areas (#) and cartilage ulceration in others
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(thick arrows); periosteal bone proliferation (not shown); moderate inflammatory infiltrates
consisting of histiocytes, plasma cells, and neutrophils. H&E staining, 100×.
(C) Proximal intertarsal joint (central and fourth tarsal bones) of mouse treated with
compound 7 (0.5mg/kg). Severe pannus with moderate multifocal articular cartilage erosion
and ulceration (thick arrows); bone lysis and destruction (thin arrows) with periosteal
proliferation; histiocytic and neutrophilic infiltration. H&E staining; 100×
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FIGURE 7.
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A) Relative amounts of collagen II antibody in terms of absorbance was measured in
different treatment groups. Serum was collected from blood samples of mice that developed
arthritis and treatment groups as well as controls. These samples were added in triplicate
into each well (50 μL). Immulon II plates were coated with bovine type II collagen and
incubated. After washing, bound anti-collagen Abs were determined using HRP-labeled goat
anti-mouse IgG Readings were in triplicate, and the experiment was repeated twice. The
figure clearly indicates the difference between collagen II Ab levels in the arthritis group
those in groups treated with compound 7. Control peptide groups also showed higher
collagen II Ab levels than the compound 7-treated groups.
B) Levels of IFN-γ were measured in different groups of DBA/1 mice using BD biosciences
bead array method and flow cytometry. The compound 7-treated group at 1 mg/kg showed
significant reduction in levels of IFN-γ compared to the arthritic group.
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C) Cells from spleens of mice primed and challenged with compound 7 for antigenicity.
DBA-1 female mice were immunized with 100 μg of native type II collagen emulsified with
CFA 12 days prior to the actual day of assay. Antigen-presenting cells were generated from
naïve mice without type II collagen injection. Cells were isolated from the immunized and
control mice. After harvesting the cells, compound 7 was added at different concentrations.
Plates were incubated for 45 min in a CO2 incubator at 37 °C. This was followed by the
final step of reading the fluorescence using a celltiter-glo (CTG) assay (Promega, Inc.) with
a plate reader. Con A was used as positive control (p<0.05).
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FIGURE 8.

Stability of compound 7 in serum by MALDI-TOF. Y-axis represents amount of intact
compound 7 remaining. 200 μL of stock solutions of compound 7 was treated with 1 mL
mouse serum. At different time points ranging from 0 min to 48 h, 100 μL of the above
sample was withdrawn and treated with 500 μL of chilled acetonitrile for compound 7
extraction. These samples were analyzed by TOF-MS. The spectra were acquired after
calibration of the instrument with a peptide standard. A minimum of 500 laser shots per
sample was used to generate each mass spectrum. Leuprolide was used as an internal
standard against which the sample peaks were ing 0.05% Tweenive intensity is plotted with
respect to time, and data are from triplicate experiments.
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